As of today (2024-06-09), the Forward Annual Dividend Yield of Rain Oncology is 0.00%.
As of today (2024-06-09), the Trailing Annual Dividend Yield of Rain Oncology is 0.00%.
RAIN's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.68 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison of Rain Oncology's Forward Dividend Yield %
For the Biotechnology subindustry, Rain Oncology's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rain Oncology's Forward Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rain Oncology's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Rain Oncology's Forward Dividend Yield % falls into.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Rain Oncology Forward Dividend Yield % Related Terms
Thank you for viewing the detailed overview of Rain Oncology's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Rain Oncology (Rain Oncology) Business Description
Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RAIN has been successfully added to your